Tetra Discovery Partners Inc., of Grand Rapids, Mich., said the FDA accepted the IND for BPN-14770, a selective small-molecule inhibitor of the phosphodiesterase type-4D enzyme, which research suggests may be useful in the treatment of fragile X syndrome and possibly other autism spectrum disorders.